Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys.
about
Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251...Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challengeRecombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia.Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virionsRecombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail.Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectorsPathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing GagALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiencyRev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques.Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus.Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.A vaccine for HIV type 1: the antibody perspective.Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.Blockade of T cell costimulation reveals interrelated actions of CD4+ and CD8+ T cells in control of SIV replicationCorrelation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.Control of viremia and maintenance of intestinal CD4(+) memory T cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge.DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.Limited protection from a pathogenic chimeric simian-human immunodeficiency virus challenge following immunization with attenuated simian immunodeficiency virus.Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus.Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses.Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f
P2860
Q24798276-FE8DD315-48D8-46EA-931A-6B2C0331CF4DQ30431941-5B6D43EC-8690-47D4-99EC-300AEAE9EC0DQ33676444-6AAF90FD-F322-46B6-A67F-D85E419ADC74Q33782797-09FE0B59-295B-44F3-8819-F83BFFA18125Q33783429-B9DCA139-6D80-4079-A22A-E82FC5042A84Q33783960-0A76DA2C-FE96-46F9-8C7C-F1E39A9AB1A3Q33784692-5CC7AD20-4477-4947-B8E4-A26116EEB131Q33787271-2E718ED6-9F05-437B-AE9C-9A91EAD7B1ADQ33800760-187C75EE-F9F1-46FD-A6C1-3A2C58057A44Q33834814-DA1AAE63-83B5-4802-B6F5-FF49D9F4AEC5Q33852720-F71E46A8-0ECD-4014-920D-B1CA4F716D55Q34007084-FCA80026-C3DB-46EC-92D3-FE3AAAB4BDD4Q34150125-DFC67C5B-1F47-490B-9000-A16C30165069Q34226966-16F52D52-3EF2-442E-931D-A5B4D26BCD60Q34228487-A8B7A6CB-D919-4429-9C27-86D92F40009CQ34326613-859DE2DE-4E29-44B6-A478-4E4FFC47DBC6Q34327256-90B5CE19-9AA5-414D-9959-257F705A46D5Q34354961-0AE40367-BA3F-42E2-A1BF-ED06126842C9Q35155380-A3310A48-BBD7-4070-976F-58F713597732Q35896178-C1474A07-48FB-4E4A-ABB3-FA5949421AECQ35948073-FD3C8EF8-61A3-4485-814C-FE8BC61DCCFEQ36037760-09D0ADF5-5AB5-40DA-AFE7-6043AA27B0ECQ36404673-44EE06BD-72D8-4ECE-B624-D99E653B6009Q36752214-4F14E4EE-0C57-406B-8313-BD69E42BB50EQ37010374-FA15EF0E-AEE7-4685-A2D7-64BB8BD6D0B9Q37171639-E5B1AF79-0192-42E4-8635-392931B2A0B5Q37181874-7397F31A-7D5F-4D61-9C94-7CBAEE827342Q39549352-7F42A79C-2267-40C1-937A-68433B440AA2Q39579973-D10771AE-754C-4014-BFE3-A959C59C834BQ39588679-45F7B481-3412-4E5B-B25A-9897C22D4F77Q39796603-F81C0B6F-E3FC-4385-BDC0-778A1B94EA14Q57075677-4AAE4D35-55A3-42C9-8EB7-CA3E16CE4638
P2860
Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@en
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@nl
type
label
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@en
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@nl
prefLabel
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@en
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@nl
P2093
P1476
Neutralizing and infection-enh ...... ult and infant rhesus monkeys.
@en
P2093
P304
P407
P577
1996-12-01T00:00:00Z